Robert E Landry is EVP Finance CFO of REGENERON PHARMACEUTICALS, INC.. Currently has a direct ownership of 23,693 shares of REGN, which is worth approximately $27.2 Million. The most recent transaction as insider was on Apr 08, 2022, when has been sold 325 shares (Common Stock) at a price of $736.48 per share, resulting in proceeds of $239,356. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 23.7K
0% 3M change
25.26% 12M change
Total Value Held $27.2 Million

Robert E Landry Transaction History

Date Transaction Value Shares Traded Shares Held Form
Apr 08 2022
SELL
Open market or private sale
$239,356 $736.48 p/Share
325 Reduced 1.12%
28,744 Common Stock
Apr 08 2022
SELL
Payment of exercise price or tax liability
$4,518,857 $736.21 p/Share
6,138 Reduced 16.7%
30,606 Common Stock
Apr 08 2022
BUY
Exercise of conversion of derivative security
$3,126,320 $390.79 p/Share
8,000 Added 19.92%
32,158 Common Stock
Apr 07 2022
SELL
Payment of exercise price or tax liability
$841,406 $716.09 p/Share
1,175 Reduced 3.89%
29,069 Common Stock
Apr 07 2022
BUY
Exercise of conversion of derivative security
$599,490 $399.66 p/Share
1,500 Added 4.73%
30,244 Common Stock
Apr 01 2022
SELL
Open market or private sale
$220,802 $698.74 p/Share
316 Reduced 1.09%
28,744 Common Stock
Mar 31 2022
SELL
Payment of exercise price or tax liability
$829,972 $700.99 p/Share
1,184 Reduced 3.91%
29,060 Common Stock
Mar 31 2022
BUY
Exercise of conversion of derivative security
$599,490 $399.66 p/Share
1,500 Added 4.73%
30,244 Common Stock
Mar 29 2022
SELL
Open market or private sale
$1,846,011 $688.04 p/Share
2,683 Reduced 8.54%
28,744 Common Stock
Mar 28 2022
SELL
Payment of exercise price or tax liability
$8,097,718 $685.26 p/Share
11,817 Reduced 27.33%
31,427 Common Stock
Mar 28 2022
BUY
Exercise of conversion of derivative security
$6,699,870 $462.06 p/Share
14,500 Added 29.77%
34,212 Common Stock
Mar 21 2022
SELL
Open market or private sale
$207,900 $693.0 p/Share
300 Reduced 1.04%
28,656 Common Stock
Mar 21 2022
SELL
Payment of exercise price or tax liability
$215,689 $691.31 p/Share
312 Reduced 1.07%
28,744 Common Stock
Mar 21 2022
BUY
Exercise of conversion of derivative security
$152,768 $381.92 p/Share
400 Added 1.36%
29,056 Common Stock
Mar 17 2022
SELL
Open market or private sale
$56,938 $686.0 p/Share
83 Reduced 0.29%
28,877 Common Stock
Mar 17 2022
SELL
Payment of exercise price or tax liability
$195,195 $682.5 p/Share
286 Reduced 0.98%
28,956 Common Stock
Mar 17 2022
BUY
Exercise of conversion of derivative security
$139,401 $381.92 p/Share
365 Added 1.23%
29,242 Common Stock
Mar 16 2022
SELL
Open market or private sale
$203,100 $677.0 p/Share
300 Reduced 1.03%
28,960 Common Stock
Dec 13 2021
SELL
Open market or private sale
$76,850 $662.5 p/Share
116 Reduced 0.39%
29,260 Common Stock
Dec 11 2021
SELL
Payment of exercise price or tax liability
$463,045 $664.34 p/Share
697 Reduced 2.32%
29,376 Common Stock
Dec 10 2021
SELL
Payment of exercise price or tax liability
$919,447 $664.34 p/Share
1,384 Reduced 4.4%
30,073 Common Stock
Dec 10 2021
SELL
Open market or private sale
$519,099 $664.66 p/Share
781 Reduced 2.54%
29,957 Common Stock
Dec 10 2021
BUY
Exercise of conversion of derivative security
$833,505 $555.67 p/Share
1,500 Added 4.55%
31,457 Common Stock
Dec 09 2021
SELL
Payment of exercise price or tax liability
$2,279,515 $657.11 p/Share
3,469 Reduced 10.14%
30,738 Common Stock
Dec 09 2021
BUY
Exercise of conversion of derivative security
$1,698,555 $399.66 p/Share
4,250 Added 11.05%
34,207 Common Stock
REL

Robert E Landry

EVP Finance CFO
Tarrytown, NY

Track Institutional and Insider Activities on REGN

Follow REGENERON PHARMACEUTICALS, INC. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells REGN shares.

Notify only if

Insider Trading

Get notified when an Regeneron Pharmaceuticals, Inc. insider buys or sells REGN shares.

Notify only if

News

Receive news related to REGENERON PHARMACEUTICALS, INC.

Track Activities on REGN